Non-Cystic Fibrosis Bronchiectasis
Purpose of Study:
This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week Phase III study to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI).All patients who complete the 52-week double-blind treatment period on investigational product (IP) may be eligible to continue into an open-label extension (OLE), during which all patients will receive benralizumab.The OLE treatment period is intended to allow patients at least one year of treatment with open label benralizumab.
July 21, 2021 - June 10, 2021
Type of Study:
Name: AstraZeneca Clinical Study Information Center
Email: [email protected]